Agios Pharmaceuticals (AGIO) Revenue (2012 - 2026)

Agios Pharmaceuticals' Revenue history runs 14 years deep, the most recent figure standing at $20.7 million for Q1 2026.

• Quarterly Revenue rose 137.75% year-over-year to $20.7 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $66.0 million (up 78.34% YoY) and the FY2025 annual result came in at $54.0 million, up 48.03% from the prior year.
• Revenue was $20.7 million for Q1 2026 at Agios Pharmaceuticals, up from $20.0 million in the prior quarter.
• Across five years, Revenue topped out at $20.7 million in Q1 2026 and bottomed at $832000.0 in Q1 2022.
• A 5-year average of $9.0 million and a median of $8.2 million in 2024 frame the typical range for Revenue.
• Annual changes were most pronounced in 2023 — Revenue jumped 574.16% — and 2025, when it increased 6.56%.
• Agios Pharmaceuticals' Revenue stood at $4.3 million in 2022, then surged by 64.8% to $7.1 million in 2023, then jumped by 51.06% to $10.7 million in 2024, then soared by 86.09% to $20.0 million in 2025, then gained by 3.9% to $20.7 million in 2026.
• Business Quant data shows AGIO's Revenue at $20.7 million in Q1 2026, $20.0 million in Q4 2025, and $12.9 million in Q3 2025.